NIDA Research Education Program for Clinical Researchers and Clinicians (R25)

The summary for the NIDA Research Education Program for Clinical Researchers and Clinicians (R25) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

NIDA Research Education Program for Clinical Researchers and Clinicians (R25): Purpose: The NIDA Research Education Program will support research education and training for those in clinically focused careers. Participants (those receiving the research education and training) should be training for careers as clinical researchers, clinicians/service providers, or optimally, a combination of the two. This mechanism may not be used for support of non-research related clinical training. In addition, applicant organizations may only propose research education experiences at the following levels of professional career development: medical/graduate student, postdoctoral fellow, medical resident, and/or independent scientist. Research education and training activities may be in any topic area related to substance use/abuse/addiction; however, the following are examples of particular relevance to this FOA: etiology; clinical assessment and diagnostics; treatment; prevention; health services; clinical neuroscience; medical consequences of drug abuse; and pre-clinical research as it pertains to translational research. Interdisciplinary research education is encouraged and may include co-morbid conditions and consequences of drug use such as HIV/AIDS. Education partnerships and collaborations are also encouraged. Mechanism of Support: This FOA will use the NIH Research Education (R25) grant mechanism. Research education programs may not be transferred from one institution to another, unless strongly justified (see Section VI.2). Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research education program will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

Federal Grant Title:	NIDA Research Education Program for Clinical Researchers and Clinicians (R25)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-10-173
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	Sep 07, 2012
Original Application Deadline:	Sep 07, 2012
Posted Date:	Apr 20, 2010
Creation Date:	Apr 20, 2010
Archive Date:	Oct 08, 2012
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...